Opportunity Information: Apply for RFA AI 20 055
The National Institutes of Health (NIH) offered this discretionary grant opportunity, RFA-AI-20-055, titled "Understanding Evolutionary Dynamics of Influenza to Inform and Improve Vaccine Strain Selection (R01 Clinical Trial Not Allowed)." It is an R01 research project grant in the health area (CFDA 93.855) focused on seasonal influenza and the persistent challenge of keeping vaccine strains aligned with what actually circulates each year. The core aim is to fund research that improves scientific understanding of how seasonal influenza viruses evolve over time, especially in ways that change their antigenic properties, so that the field can better anticipate which new variants are likely to emerge and spread and, as a result, make more accurate vaccine strain selection decisions.
The main purpose of the funding is to strengthen the evidence base behind influenza vaccine strain selection by advancing knowledge of influenza evolutionary dynamics. In practical terms, this means supporting studies that clarify how and why influenza viruses accumulate mutations, how those mutations affect antigenic drift, and what ecological, immunological, and population-level forces shape which variants become dominant. By improving the ability to predict emergence and trajectory of antigenic variants, the research supported under this FOA is intended to reduce mismatches between vaccine strains and circulating strains, which can translate into better vaccine effectiveness across influenza seasons.
This FOA uses the R01 mechanism and explicitly states "Clinical Trial Not Allowed," signaling that the proposed work should be basic, computational, analytical, or preclinical in nature rather than interventional studies in humans where participants are prospectively assigned to receive an intervention. Applicants could still potentially use human-derived data or specimens, surveillance datasets, sequence repositories, serology panels, or observational/retrospective analyses, as long as the proposed project does not meet the NIH definition of a clinical trial. The emphasis is on research that builds predictive capacity and improves strain-selection decisions rather than testing interventions in a trial framework.
Eligibility is broad and includes many common applicant types: state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (outside of higher education); for-profit organizations other than small businesses; and small businesses. The announcement also highlights additional eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). This broad eligibility suggests NIH intended to encourage participation across diverse institutional types and geographies, including international partners, which is relevant given the global nature of influenza evolution and spread.
Key administrative details included an original closing date of February 11, 2021, and an award ceiling of $500,000. The listing indicates the opportunity was created on September 24, 2020. While the number of expected awards is not specified in the provided text, the ceiling gives a sense of the anticipated maximum annual budget level per award (as typically presented in FOA summaries), and applicants would generally be expected to propose a scope of work consistent with that cap.
Overall, the opportunity is best understood as NIH support for influenza evolution research tightly connected to public-health decision-making, with the specific downstream objective of improving seasonal vaccine strain selection. Projects responsive to this FOA would likely center on mechanisms and models of antigenic drift, evolutionary forecasting, integration of genetic and antigenic data, and approaches that turn surveillance and laboratory findings into better predictions about which strains are most likely to predominate in upcoming seasons, all while staying clearly outside the bounds of a clinical trial.Apply for RFA AI 20 055
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Understanding Evolutionary Dynamics of Influenza to Inform and Improve Vaccine Strain Selection (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2020-09-24.
- Applicants must submit their applications by 2021-02-11. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the full title and identifier of this grant opportunity?
This discretionary NIH funding opportunity is RFA-AI-20-055, titled "Understanding Evolutionary Dynamics of Influenza to Inform and Improve Vaccine Strain Selection (R01 Clinical Trial Not Allowed)."
Which federal agency is offering this opportunity?
The opportunity is offered by the National Institutes of Health (NIH).
What grant mechanism does this opportunity use?
This opportunity uses the R01 research project grant mechanism.
What is the program area or CFDA listing associated with this funding?
The opportunity is listed in the health area and references CFDA 93.855.
What problem is this FOA trying to address?
It targets the ongoing challenge of seasonal influenza vaccine strain selection, specifically the risk of mismatch between vaccine strains and the strains that actually circulate in a given season.
What is the main purpose of the funding?
The main purpose is to improve the evidence base behind influenza vaccine strain selection by advancing scientific understanding of how seasonal influenza viruses evolve over time, especially when evolution changes antigenic properties (antigenic drift).
What are the core scientific goals of projects under this FOA?
Projects are intended to clarify how and why influenza viruses accumulate mutations, how those mutations affect antigenic drift, and what ecological, immunological, and population-level forces shape which variants become dominant.
How is this research expected to improve public health outcomes?
By improving the ability to anticipate which antigenic variants are likely to emerge and spread, the research is intended to reduce mismatches between vaccine strains and circulating strains, which can translate into improved vaccine effectiveness across influenza seasons.
What kinds of approaches are emphasized by this opportunity?
The emphasis is on research that builds predictive capacity and supports better strain-selection decisions. The FOA description points toward work involving mechanisms and models of antigenic drift, evolutionary forecasting, and integration of genetic and antigenic data using surveillance and laboratory findings to improve predictions about upcoming seasons.
Does this FOA allow clinical trials?
No. The FOA explicitly states "Clinical Trial Not Allowed," meaning proposed work should not meet the NIH definition of a clinical trial (for example, prospective assignment of human participants to an intervention).
If clinical trials are not allowed, what types of studies are appropriate?
The FOA framing indicates appropriate studies are basic, computational, analytical, or preclinical in nature, focused on understanding and forecasting influenza evolutionary dynamics rather than testing interventions through a clinical trial design.
Can applicants use human data or human-derived specimens without running a clinical trial?
Yes, the description indicates applicants could use human-derived data or specimens, surveillance datasets, sequence repositories, serology panels, or observational/retrospective analyses, as long as the overall project does not meet the NIH definition of a clinical trial.
Is the focus limited to a specific type of influenza?
The FOA focuses on seasonal influenza and how seasonal influenza viruses evolve over time in ways that affect antigenic properties and vaccine strain alignment.
What is meant by improving "vaccine strain selection" in this context?
It refers to improving the scientific basis and predictive ability used to choose which influenza strains should be included in seasonal vaccines, aiming to better match what will circulate in future seasons.
Who is eligible to apply?
Eligibility is broad and includes: state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (outside of higher education); for-profit organizations other than small businesses; and small businesses.
Are minority-serving and community-based institutions included in the eligible applicant types?
Yes. The opportunity highlights additional eligible categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving institutions, HBCUs, TCCUs, and faith-based or community-based organizations.
Can federal agencies apply?
Yes. Eligible applicant categories include eligible federal agencies.
Are U.S. territories or regional organizations eligible?
Yes. The FOA indicates U.S. territories or possessions and regional organizations are eligible applicant categories.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The eligibility list includes non-U.S. entities (foreign organizations), reflecting the global nature of influenza evolution and spread.
What is the maximum award amount listed for this opportunity?
The listing provides an award ceiling of $500,000.
Does the provided information specify the number of expected awards?
No. The provided text states that the number of expected awards is not specified.
What was the original closing date for applications?
The original closing date listed is February 11, 2021.
When was this opportunity created?
The listing indicates the opportunity was created on September 24, 2020.
How should applicants think about project scope relative to the budget ceiling?
Based on the provided summary, applicants would generally be expected to propose a scope of work consistent with the $500,000 award ceiling as a maximum annual budget level per award (as typically presented in FOA summaries).
What would make a project "responsive" to this FOA based on the description?
Responsive projects would be tightly connected to improving understanding of influenza evolutionary dynamics in ways that inform vaccine strain selection, such as studying antigenic drift mechanisms, developing or improving evolutionary forecasting, and integrating genetic and antigenic data to predict which variants are most likely to predominate, while clearly staying outside the bounds of a clinical trial.
Browse more opportunities from the same category: Health
Next opportunity: NHLBI Program Project Applications (P01 Clinical Trials Optional)
Previous opportunity: U.S.-Nigeria Exchange on Farmer-Herder Conflict Resolution Project
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 20 055
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 20 055) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cohort Studies To Improve Our Understanding of Influenza Immunity, Vaccine Response and Effectiveness in Older Adults (65 years and older) (U01 Clinical Trial Not Allowed) Apply for RFA AI 20 060 Funding Number: RFA AI 20 060 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed) Apply for RFA AI 20 057 Funding Number: RFA AI 20 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed) Apply for PAR 21 027 Funding Number: PAR 21 027 Agency: National Institutes of Health Category: Health Funding Amount: $480,000 |
| A Multidisciplinary Approach to Study Vaccine-elicited Immunity and Efficacy against Malaria (U01 Clinical Trial Not Allowed) Apply for RFA AI 20 064 Funding Number: RFA AI 20 064 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional) Apply for PAR 20 307 Funding Number: PAR 20 307 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Coccidioidomycosis Collaborative Research Centers (U19 Clinical Trial Not Allowed) Apply for RFA AI 20 056 Funding Number: RFA AI 20 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional) Apply for PAR 20 308 Funding Number: PAR 20 308 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional) Apply for PAR 20 306 Funding Number: PAR 20 306 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| From Genomic Association to Causation: A Convergent Neuroscience Approach to Linking Levels of Analysis for Understanding Neuropsychiatric Disorders (U19 Clinical Trial Optional) Apply for RFA MH 21 165 Funding Number: RFA MH 21 165 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed) Apply for PAR 21 032 Funding Number: PAR 21 032 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Technologies for the In vivo Delivery of Gene Therapeutics for an HIV Cure (R01 Clinical Trial Not Allowed) Apply for RFA AI 20 076 Funding Number: RFA AI 20 076 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed) Apply for PAR 21 037 Funding Number: PAR 21 037 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) Apply for PAR 21 055 Funding Number: PAR 21 055 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) Apply for PAR 21 054 Funding Number: PAR 21 054 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Improving Health Status and Human Capital in Senegal Apply for 72068521APS00001 Funding Number: 72068521APS00001 Agency: Senegal USAID-Dakar Category: Health Funding Amount: $88,000,000 |
| NINDS Research Education Programs for Residents and Fellows in Neurological Disorders and Stroke (R25 - Clinical Trial Not Allowed) Apply for PAR 20 311 Funding Number: PAR 20 311 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) Apply for PAR 21 040 Funding Number: PAR 21 040 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Treatments for Lewy Body Dementias--Exploratory Clinical Trial (U01 Clinical Trial Required) Apply for RFA NS 21 008 Funding Number: RFA NS 21 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Regional Technology Transfer Accelerator Hubs for IDeA States (STTR) (UT2 - Clinical Trial Not Allowed) Apply for RFA GM 21 001 Funding Number: RFA GM 21 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional) Apply for RFA MD 21 001 Funding Number: RFA MD 21 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 20 055", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.